PSYCHEDELIC RESEARCH SNAPSHOT

Psilocybin & Late-Life Mental Health: A Comprehensive Review

MAPS CANADA

BACKGROUND

The global population aged 60+ now exceeds 1 billion, with the oldest demographic projected to double by 2050

Population aging highlights the urgent need to address mental health issues in older adults such as depression, social isolation, and existential distress


Among older adults, these mental health conditions are associated with greater disability, higher rates of institutionalization, increased mortality, and greater healthcare utilization

MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES
MAPS CANADA

WHY IS TREATING OLDER ADULT MENTAL HEALTH MORE CHALLENGING?

Traditional mental health treatments (e.g., antidepressants) may have reduced effectiveness or be unsuitable for older adults for various reasons. These include:

- Age-related physiological changes (e.g., serotonin receptor density, hormones, drug metabolism)
- Potential for negative interactions with other medications
- Different symptom patterns than younger adults (e.g., cognitive and motivational more common then mood symptoms).
- Higher vulnerability to cognitive side-effects



MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES

MAPS CANADA

COULD PSILOCYBIN HELP?

Loneliness, social isolation, concerns about mortality, and reduced sense of meaning or purpose are prevalent in older adults

Clinical trials suggest that psilocybin-assisted therapy can provide fast and lasting relief from depression and existential distress and improve social connectedness, meaning, and well-being

The serotonin system, which helps regulate mood and emotions, goes through changes with age, including a decline in 5-HT2A receptors that may increase vulnerability to depression




Psilocybin binds and activates 5-HT2A receptors and promotes neuroplasticity, both of which may assist with the chemical and structural changes seen in older adults

MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES

MAPS CANADA

SO WHAT'S THE PROBLEM?

Most research on psilocybin and depression includes participants aged 21-65 years, leaving older adults understudied



A systematic review of 36 psychedelic trials with more than 1,400 participants found only 19 participants aged 65+

Further, many studies exclude people with heart disease, multiple medications, memory problems, or frailty, making it harder for older adults to take part in research



MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES
MAPS CANADA

SAFETY CONSIDERATIONS & AGE-RELATED FACTORS

1. BIOLOGICAL CHANGES & DOSING

Psilocybin dosing may need to differ in older adults because age-related changes in metabolism, body composition, kidney and liver function can increase drug exposure and make responses less predictable

2. CARDIOVASCULAR SAFETY

Psilocybin can cause temporary increases in blood pressure and heart rate, so cardiovascular screening and monitoring are important in older adults, although serious cardiac events have not been reported in the small number of healthy older adults studied to date

MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES
MAPS CANADA

SAFETY CONSIDERATIONS & AGE-RELATED FACTORS

3. DRUG INTERACTIONS

Because older adults often take multiple medications that can affect how psilocybin is metabolized, careful medication review and monitoring are essential to minimize drug interactions and ensure safe treatment

4. PSYCHOLOGICAL SAFETY

Because psilocybin can profoundly affect perception, emotions, and sense of self, older adults may require enhanced cognitive screening, preparation, support, and follow-up to safely manage the psychological challenges that can arise during and after treatment

CONCLUSION

Older adults may be especially good candidates for psilocybin.

Age-related changes in serotonin signaling and the limited effectiveness of conventional antidepressants in later life may make psilocybin a promising treatment for late-life depression.

Safety considerations differ in older adults.

Changes in metabolism, cognition, cardiovascular health, and polypharmacy require tailored screening, monitoring, and dosing approaches.

More geriatric-specific research is needed.

The focus must shift from whether psilocybin works to how it can be delivered safely, ethically, and effectively within geriatric and palliative care settings.

REFERENCE

Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety

Gerasimos N. Konstantinou, Joshua Rosenblat, Sarah Hales, Muhammad Ishrat Husain, & Daniel M. Blumberger (2026)

General Hospital Psychiatry, 98, 54–63. https://doi.org/10.1016/j.genhosppsych.2025.12.005

Artwork by: Paulina Colours

MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES

MAPS CANADA